As technology has improved over time, it has enabled us to achieve a much deeper knowledge of the human genome as we have been able to develop the tools which have granted us much greater insight into how the genetic code of an individual and epigenetic regulation can influence different aspects of disease development and progression. Cancer is known on a basic fundamental level to be caused by genetic mutations and epigenetic dysregulation, which go on to be transcribed in an unhealthy fashion leading to tumor development, and with more advances methodology to sequence the genes clinicians can now identify the location of the mutation, and can also categorize the mutation as being germline, chromosomal, frameshift or point mutations. With further developments, the technology is becoming more and more streamlined, enabling genetic sequencing to be completed more quickly and affordably, and is enabling more tailored and importantly more prompt therapeutic interventions in cancer care. The limitations of next Generation Cancer sequencing remains to be seen, and this new frontier in cancer discovery will undoubtedly be a source of groundbreaking oncological discoveries for years to come, which is why we see this subject as needing more attention from the scientific community to really fulfill the potential of this technology.
Next Generation Sequencing (NGS) has developed greatly over recent years and is commonly used by clinicians for whole genome and exome sequencing, transcriptome and epigenetic sequencing, targeted region sequencing among other utilizations. This gives great opportunities for therapy and patient care, with the findings being able to give great insights into disease management and treatment, genetic counseling, and risk assessment of diseases later in life. A more recent development on how this technology can be used is the personalization of cancer treatments to the specific needs of the patient in line with the cancer they have been diagnosed with; the combination of the deeper understanding into the disease and their progression, paired with patient specific treatments has the potential to revolutionize the way cancer is diagnosed and subsequently treated.
Apart from clinical care, Next Generation Sequencing (NGS) also has become a regular technology in the cancer research field. Transcriptome profiling upon different treatment approaches uncover the novel therapeutic mechanisms. Epigenetic profiling with Chip-seq and ATAC-seq gives great opportunities for new therapeutic target discovery. Recently, cancer clonal evolution and cancer heterogeneities are thought to be important fields in cancer study. The dynamics of cancer evolution are complex with highly variable patterns of genetic diversity and resultant clonal architecture. Single cell RNA-Seq, a technology that analyzes transcriptomes of complex tissues at single-cell levels, can identify differential gene expression and epigenetic factors caused by mutations in unicellular genomes. ScRNA-seq provides new technical means for further development of tumor research and is expected to make significant breakthroughs in this field. By combining these different technologies, we have a more comprehensive and multidimensional platform for cancer research.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- NGS used to discover new mutations linking to cancer development and progression
- New therapeutic mechanisms derived from NGS
- Personalization of cancer care via - NGS findings
- Use of NGS to predict disease outcomes and risks
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
As technology has improved over time, it has enabled us to achieve a much deeper knowledge of the human genome as we have been able to develop the tools which have granted us much greater insight into how the genetic code of an individual and epigenetic regulation can influence different aspects of disease development and progression. Cancer is known on a basic fundamental level to be caused by genetic mutations and epigenetic dysregulation, which go on to be transcribed in an unhealthy fashion leading to tumor development, and with more advances methodology to sequence the genes clinicians can now identify the location of the mutation, and can also categorize the mutation as being germline, chromosomal, frameshift or point mutations. With further developments, the technology is becoming more and more streamlined, enabling genetic sequencing to be completed more quickly and affordably, and is enabling more tailored and importantly more prompt therapeutic interventions in cancer care. The limitations of next Generation Cancer sequencing remains to be seen, and this new frontier in cancer discovery will undoubtedly be a source of groundbreaking oncological discoveries for years to come, which is why we see this subject as needing more attention from the scientific community to really fulfill the potential of this technology.
Next Generation Sequencing (NGS) has developed greatly over recent years and is commonly used by clinicians for whole genome and exome sequencing, transcriptome and epigenetic sequencing, targeted region sequencing among other utilizations. This gives great opportunities for therapy and patient care, with the findings being able to give great insights into disease management and treatment, genetic counseling, and risk assessment of diseases later in life. A more recent development on how this technology can be used is the personalization of cancer treatments to the specific needs of the patient in line with the cancer they have been diagnosed with; the combination of the deeper understanding into the disease and their progression, paired with patient specific treatments has the potential to revolutionize the way cancer is diagnosed and subsequently treated.
Apart from clinical care, Next Generation Sequencing (NGS) also has become a regular technology in the cancer research field. Transcriptome profiling upon different treatment approaches uncover the novel therapeutic mechanisms. Epigenetic profiling with Chip-seq and ATAC-seq gives great opportunities for new therapeutic target discovery. Recently, cancer clonal evolution and cancer heterogeneities are thought to be important fields in cancer study. The dynamics of cancer evolution are complex with highly variable patterns of genetic diversity and resultant clonal architecture. Single cell RNA-Seq, a technology that analyzes transcriptomes of complex tissues at single-cell levels, can identify differential gene expression and epigenetic factors caused by mutations in unicellular genomes. ScRNA-seq provides new technical means for further development of tumor research and is expected to make significant breakthroughs in this field. By combining these different technologies, we have a more comprehensive and multidimensional platform for cancer research.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- NGS used to discover new mutations linking to cancer development and progression
- New therapeutic mechanisms derived from NGS
- Personalization of cancer care via - NGS findings
- Use of NGS to predict disease outcomes and risks
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
